PO-0642 TREATMENT OUTCOMES AND PATTERNS OF FAILURE IN EARLY STAGE UNFAVOURABLE HODGKINÍS LYMPHOMA
Doondi Phani Kumar, Shripad Banavali, M.A. Muckaden(Homi Bhabha National Institute), Tanuja Shet(Tata Memorial Hospital), Hari Menon(All India Institute of Medical Sciences), Reena Nair(Tata Medical Center), Manju Sengar(Homi Bhabha National Institute), B Arora(Tata Memorial Hospital), Siddharth Laskar(Homi Bhabha National Institute), Sumeet Gujral(Homi Bhabha National Institute)
Cited by 0
Related Papers
Consolidation Radiation After Complete Remission in Hodgkin's Disease Following Six Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy: Is There a Need?
|Journal of Clinical Oncology|2003|202
Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey
|The Lancet Oncology|2021|170
Lymphoma of the Gastrointestinal Tract
|Unknown|2022|146
Barriers in access to oncology drugs — a global crisis
|Nature Reviews Clinical Oncology|2022|122
Common Sense Oncology: outcomes that matter
|The Lancet Oncology|2023|101